Literature DB >> 23216836

VEGFA and tumour angiogenesis.

L Claesson-Welsh1, M Welsh.   

Abstract

In this review we summarize the current understanding of signal transduction downstream of vascular endothelial growth factor A (VEGFA) and its receptor VEGFR2, and the relationship between these signal transduction pathways and the hallmark responses of VEGFA, angiogenesis and vascular permeability. These physiological responses involve a number of effectors, including extracellular signal-regulated kinases (ERKs), Src, phosphoinositide 3 kinase (PI3K)/Akt, focal adhesion kinase (FAK), Rho family GTPases, endothelial NO and p38 mitogen-activated protein kinase (MAPK). Several of these factors are involved in the regulation of both angiogenesis and vascular permeability. Tumour angiogenesis primarily relies on VEGFA-driven responses, which to a large extent result in a dysfunctional vasculature. The reason for this remains unclear, although it appears that certain aspects of the VEGFA-stimulated angiogenic milieu (high level of microvascular density and permeability) promote tumour expansion. The high degree of redundancy and complexity of VEGFA-driven tumour angiogenesis may explain why tumours commonly develop resistance to anti-angiogenic therapy targeting VEGFA signal transduction.
© 2012 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23216836     DOI: 10.1111/joim.12019

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  242 in total

Review 1.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

Review 2.  Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis comparable with mechanisms seen in inflammatory pathways? Part I: historical observations and clinical perspectives on the etiology of increased CSF protein levels, CSF clotting, and communicating hydrocephalus: a comprehensive review.

Authors:  Yosef Laviv; Burkhard S Kasper; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2017-03-07       Impact factor: 3.042

3.  Perlecan domain V inhibits amyloid-β induced brain endothelial cell toxicity and restores angiogenic function.

Authors:  Christi Parham; Lisa Auckland; Jessica Rachwal; Douglas Clarke; Gregory Bix
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 4.  Drugs derived from phage display: from candidate identification to clinical practice.

Authors:  Andrew E Nixon; Daniel J Sexton; Robert C Ladner
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 5.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

6.  IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis.

Authors:  Elisa Ferretti; Emma Di Carlo; Emanuela Ognio; Giulio Fraternali-Orcioni; Anna Corcione; Beatrice Belmonte; Jean Louis Ravetti; Claudio Tripodo; Domenico Ribatti; Vito Pistoia
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

7.  NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

Review 8.  Angiogenesis and hypoxia in the kidney.

Authors:  Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2013-03-05       Impact factor: 28.314

9.  NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Mol Carcinog       Date:  2018-12-21       Impact factor: 4.784

10.  Silencing of HOXB9 suppresses cellular proliferation, angiogenesis, migration and invasion of prostate cancer cells.

Authors:  Hao Xu; Shangjun Wu; Xin Shen; Ding Wu; Zhenguo Qin; Hao Wang; Xiaogang Chen; Xiaoqing Sun
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.